PMADS

Id:	acc0767
Group:	2sens
Protein:	FRS2alpha
Gene Symbol:	FRS2
Protein Id:	Q8WU20
Protein Name:	FRS2_HUMAN
PTM:	phosphorylation
Site:	unclear
Site Sequence:
Disease Category:	Cancer
Disease:	Breast Cancer
Disease Subtype:	TNBC
Disease Cellline:	SUM 52PE
Disease Info:
Drug:	Alofanib
Drug Info:	-
Effect:	modulate
Effect Info:	"Alofaniib inhibits the phosphorylation of FRS2alpha, thereby suppressing tumors."
Note:
Score:	4.0
Pubmed(PMID):	27136102
Sentence Index:	27136102_3-4
Sentence:	"In the present study, we further showed that alofanib inhibited phosphorylation of FRS2alpha with the half maximal inhibitory concentration (IC50) values of 7 and 9 nmol/l in cancer cells expressing different FGFR2 isoforms. In a panel of four cell lines representing several tumour types (triple-negative breast cancer, melanoma, and ovarian cancer), alofanib inhibited FGF-mediated proliferation with 50% growth inhibition (GI50) values of 16-370 nmol/l. Alofanib dose dependently inhibited the proliferation and migration of human and mouse endothelial cells (GI50 11-58 nmol/l) compared with brivanib and bevacizumab."

Sequence & Structure:

MGSCCSCPDKDTVPDNHRNKFKVINVDDDGNELGSGIMELTDTELILYTRKRDSVKWHYLCLRRYGYDSNLFSFESGRRCQTGQGIFAFKCARAEELFNMLQEIMQNNSINVVEEPVVERNNHQTELEVPRTPRTPTTPGFAAQNLPNGYPRYPSFGDASSHPSSRHPSVGSARLPSVGEESTHPLLVAEEQVHTYVNTTGVQEERKNRTSVHVPLEARVSNAESSTPKEEPSSIEDRDPQILLEPEGVKFVLGPTPVQKQLMEKEKLEQLGRDQVSGSGANNTEWDTGYDSDERRDAPSVNKLVYENINGLSIPSASGVRRGRLTSTSTSDTQNINNSAQRRTALLNYENLPSLPPVWEARKLSRDEDDNLGPKTPSLNGYHNNLDPMHNYVNTENVTVPASAHKIEYSRRRDCTPTVFNFDIRRPSLEHRQLNYIQVDLEGGSDSDNPQTPKTPTTPLPQTPTRRTELYAVIDIERTAAMSNLQKALPRDDGTSRKTRHNSTDLPM

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

FRS2-Ser169
Cancer	Intensity
BRCA	-0.012
COAD	0.97
HGSC	0.911
ccRCC
GBM	-1.864
HNSC	-0.527
LUAD
LUSC	-0.152
non_ccRCC
PDAC
UCEC	0.673

FRS2-Ser177
Cancer	Intensity
BRCA
COAD
HGSC	-0.707
ccRCC
GBM	0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

FRS2-Ser211
Cancer	Intensity
BRCA
COAD	-0.094
HGSC	1.768
ccRCC
GBM	-1.315
HNSC	0.669
LUAD	-0.711
LUSC	-0.401
non_ccRCC	-0.363
PDAC	-0.723
UCEC	1.17

FRS2-Ser221
Cancer	Intensity
BRCA	-1.669
COAD
HGSC
ccRCC	0.094
GBM	-1.286
HNSC
LUAD	0.146
LUSC	0.271
non_ccRCC	1.123
PDAC	1.061
UCEC	0.261

FRS2-Ser292
Cancer	Intensity
BRCA	0.475
COAD	-0.199
HGSC	1.017
ccRCC	0.319
GBM	-2.14
HNSC	1.276
LUAD	-0.612
LUSC	-0.123
non_ccRCC
PDAC
UCEC	-0.013

FRS2-Ser327
Cancer	Intensity
BRCA
COAD	0.707
HGSC	-0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

FRS2-Ser354
Cancer	Intensity
BRCA	-1.625
COAD	0.072
HGSC	-1.37
ccRCC
GBM	1.469
HNSC	0.439
LUAD	0.453
LUSC	0.678
non_ccRCC	-0.536
PDAC
UCEC	0.421

FRS2-Ser428
Cancer	Intensity
BRCA	0.937
COAD	1.034
HGSC	0.886
ccRCC	-0.682
GBM	-2.06
HNSC	-0.58
LUAD	-0.132
LUSC	-0.767
non_ccRCC	1.257
PDAC	0.181
UCEC	-0.074

FRS2-Ser445
Cancer	Intensity
BRCA	-0.499
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	1.151
LUSC
non_ccRCC
PDAC
UCEC	-0.652

FRS2-Ser503
Cancer	Intensity
BRCA
COAD	-0.707
HGSC	0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

FRS2-Thr132
Cancer	Intensity
BRCA
COAD
HGSC	-0.707
ccRCC
GBM	0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

FRS2-Thr135
Cancer	Intensity
BRCA
COAD
HGSC	-1.474
ccRCC	0.233
GBM	1.275
HNSC
LUAD
LUSC
non_ccRCC
PDAC	-0.287
UCEC	0.253

FRS2-Thr138
Cancer	Intensity
BRCA
COAD
HGSC	-0.707
ccRCC	0.707
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

FRS2-Thr210
Cancer	Intensity
BRCA
COAD
HGSC	1.251
ccRCC	-0.59
GBM
HNSC	-0.772
LUAD	-0.806
LUSC
non_ccRCC
PDAC
UCEC	0.917

FRS2-Thr227
Cancer	Intensity
BRCA
COAD
HGSC	0.707
ccRCC
GBM	-0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

FRS2-Thr288
Cancer	Intensity
BRCA
COAD	0.707
HGSC
ccRCC	-0.096
GBM	-0.536
HNSC	-1.663
LUAD	0.495
LUSC
non_ccRCC
PDAC
UCEC	1.093

FRS2-Thr328
Cancer	Intensity
BRCA
COAD	0.707
HGSC	-0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

FRS2-Thr455
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC	0.707
non_ccRCC
PDAC
UCEC	-0.707

FRS2-Thr458
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	-1.046
HNSC	0.234
LUAD	-0.466
LUSC	1.278
non_ccRCC
PDAC
UCEC

FRS2-Thr463
Cancer	Intensity
BRCA	-1.323
COAD
HGSC	1.997
ccRCC	0.773
GBM	-0.784
HNSC	0.057
LUAD	-0.834
LUSC	-0.288
non_ccRCC	0.505
PDAC	-0.103
UCEC

FRS2-Tyr290
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM	-1.34
HNSC	0.214
LUAD	0.051
LUSC
non_ccRCC
PDAC
UCEC	1.075

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb